🌟 Gilternib® 40 mg (Gilteritinib) Tablets
By Everest Pharma | 90 Tablets Pack

💥 Unlock a New Era in AML Treatment

Gilternib® 40 mg is a next-generation, targeted oral therapy designed to fight acute myeloid leukemia (AML) in adults with relapsed or refractory FLT3 mutation-positive disease. With its precision action, Gilternib offers a beacon of hope for patients needing advanced treatment options.

🔬 How It Works

Gilternib is a selective FLT3 inhibitor that disrupts the abnormal signaling driving leukemia cell growth. By halting these cancer-promoting pathways, it reduces disease burden, improves survival, and provides a meaningful clinical response where traditional treatments may fail.

💊 Product Highlights

✅ Strength: 40 mg per tablet
✅ Pack size: 90 film-coated tablets
✅ Manufacturer: Everest Pharmaceuticals Ltd.
✅ Generic name: Gilteritinib

🎯 Key Benefits

✔ Precision targeting of FLT3 mutations (ITD & TKD)
✔ Convenient once-daily dosing
✔ Oral administration — no hospital infusions
✔ Suitable with or without food
✔ Manufactured to high international quality standards

📋 Indication

• Treatment of adult patients with relapsed or refractory FLT3-mutated AML, confirmed by an approved diagnostic test.

⚠️ Important Safety Information

• Common side effects: fatigue, diarrhea, nausea, liver enzyme elevation, muscle pain

• Rare but serious: QT prolongation (heart rhythm changes), PRES (brain swelling)

• Regular monitoring (ECG, blood tests) is essential

• Not recommended during pregnancy — use effective contraception

💾 Storage Instructions

• Store below 30°C

• Keep in original packaging

• Protect from moisture and light

• Keep out of reach of children

🌐 For More Information

📞 +8801844288466
📧 npmolecule23@gmail.com
🌍 www.npmoleculeoncology.com
📍 Sector-14, Uttara, Dhaka-1230

✨ Gilternib® 40 mg — A Powerful Ally Against FLT3-Mutated AML
Bringing innovation, quality, and hope — Everest Pharma is committed to advancing cancer care.